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Aberrant DNA methylation is a distinguishing feature of cancer. Yet, how methylation affects immune surveillance and
tumor metastasis remains ambiguous. We introduce a novel method, Guide Positioning Sequencing (GPS), for precisely de-
tectingwhole-genomeDNAmethylationwith cytosine coverage as high as 96%and unbiased coverage ofGC-rich and repet-
itive regions. Systematic comparisons of GPS with whole-genome bisulfite sequencing (WGBS) found that methylation
difference between gene body and promoter is an effective predictor of gene expression with a correlation coefficient of
0.67 (GPS) versus 0.33 (WGBS).Moreover,Methylation Boundary Shift (MBS) in promoters or enhancers is capable ofmod-
ulating expression of genes associated with immunity and tumor metabolism. Furthermore, aberrant DNA methylation re-
sults in tissue-specific enhancer switching, which is responsible for altering cell identity during liver cancer development.
Altogether, we demonstrate that GPS is a powerful tool with improved accuracy and efficiency overWGBS in simultaneously
detecting genome-wide DNAmethylation and genomic variation. Using GPS, we show that aberrant DNAmethylation is as-
sociatedwith altering cell identity and immune surveillance networks, whichmay contribute to tumorigenesis andmetastasis.
[Supplemental material is available for this article.]
DNA methylation of cytosines in the metazoan genome is a sta-
ble epigenetic mark and has been intimately linked to cancer
(Feinberg et al. 2016). Aberrant DNA methylation patterns can
be found in cancer genomes and related to cancer progression
(Spencer et al. 2017). In addition, it has been shown that a high
level of methylation in promoters is likely to induce gene silenc-
ing, whereas a high level of methylation in the gene body is linked
to increased gene expression (Neri et al. 2017). However, the rela-
tionship betweenDNAmethylation in the gene body and promot-
er as well as how aberrant DNA methylation influences gene
expression during tumorigenesis and metastasis require further
exploration.
The interaction between cancer and the host immune system
is complicated, and the immune system plays a critical role in the
surveillance against cancer (Grivennikov et al. 2010; Schreiber
et al. 2011; Vinay et al. 2015). Recently, emerging evidence
showsthatTcell activationby interrupting the interactionbetween
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PDCD1andCD274 (also known as PD-1 andPD-L1) candisrupt tu-
mor cell growth;meanwhileDNAmethylations are involved in the
transition between effector and memory CD8 T cell (Akondy et al.
2017; Youngblood et al. 2017). The interruption can be mediated
by the alteration of DNA methylation (Goltz et al. 2016;
Ghoneimetal. 2017). The immune systemwas showntobecapable
of suppressing tumor growth by destroying cancer cells, while
simultaneously promoting tumor progression by establishing a fa-
vorablemicroenvironment for tumoroutgrowth (Eggert et al. 2016;
Mohmeet al. 2017).Wepostulated that epigenetic aberrations such
as aberrant DNA methylation could potentially affect immune
genes through immune-epigenetic interactions and instigate can-
cer cell evasion from the host immune system.
Bisulfite conversion of genomic DNA coupled with next-gen-
eration sequencing is generally considered the “gold standard” in
genome-wide base-resolution methylome detection (Rivera and
Ren 2013). There is, however, a built-in limitation of the bio-
informatics analysis of bisulfite sequencing, whose mapping strat-
egy is based either on wild-card aligners or three-letter aligners
(Krueger et al. 2012). Each has its set of restrictions. Wild-card
aligners achieve a higher genomic coverage, but do so at the ex-
pense of a preference toward increased DNA methylation levels,
because the extra cytosines (Cs) in a methylated read can raise
the sequence complexity to a sufficient level such that unique
alignment to the genome is maintained, while the corresponding,
unmethylated, T-containing read is discarded due to nonunique
alignment. On the other hand, three-letter aligners eliminate re-
maining Cs from bisulfite sequencing reads, which consequently
diminishes sequence complexity in that a greater percentage of
reads is discarded due to ambiguous alignment positions (Bock
2012). In light of these limitations, there is an urgent need for fur-
ther developing and optimizing the current genome-wide DNA
methylation profiling method with a focus on improving map-
ping accuracy and cost-efficiency.
To solve these problems, we developed a novel method,
Guide Positioning Sequencing (GPS) for genome-wide DNAmeth-
ylation detection. By applying GPS to detect DNA methylation in
normal liver cells and hepatoma cell lines 97L and LM3 (Li et al.
2003; Zhang et al. 2012), we investigate aberrantDNAmethylation
patterns in regulating gene expression related to tumorigenesis
and metastasis.
Results
Accurate detection of genome-wide DNA methylation by Guide
Positioning Sequencing
In this section,wepresentournovelmethod for genome-wideDNA
methylation detection. Taking advantage of both 3′→5′ exonucle-
ase and 5′→3′ polymerase activities of the T4 DNA polymerase, we
were able to obtain a DNA fragment integrated with methylcyto-
sine. The 3′ end of theDNA fragmentwith nonconvertiblemethyl-
cytosine after bisulfite treatment can act as a guide for calculating
DNA methylation of the 5′ end through pair-end sequencing
(Fig. 1A). ThisGuidePositioningSequencing (GPS)methodenables
us to detect genome-wide DNA methylation precisely with a high
cytosine coverage rate. As shown in Supplemental Figure S1A, T4
DNA polymerase synthesizes chimera fragments whose 3′ end se-
quence with dmCTP integration matched perfectly with the refer-
ence genome, whereas the 5′ end sequence without dmCTP
integration showed several C→T mismatches due to considerable
C→T conversion. To evaluate the accuracy and performance of
GPS alignment, we randomly generated onemillion pair-end reads
from the reference human genome to simulate pair-end sequenc-
ing results. With the help of the already known genome position
derived from simulated reads, we can evaluate the accuracy of
DNAmethylation detection strategies by comparing their accurate
alignment rate. We observed that the accurate alignment rate of
WGBS aligned by BSMAP (Xi and Li 2009) can be as low as
66.2%, suggesting that approximately one-third of the reads had
been discarded during alignment. The rate of accurate alignment
for GPS, on the other hand, can reach as high as 82.3%, closer to
that of the widely used genome DNA alignment tool Bowtie 2
(Langmead and Salzberg 2012) at 86.3%. With Bowtie 2, both
ends are kept to its original genome sequence (P-value <0.001,
one-tailed paired t-test) (Fig. 1B). We further observed that GPS
consistently performed better than WGBS aligned by BSMAP,
even with the increased rate of mismatches/indels (Supplemental
Fig. S1B).
Further side-by-side experimentsofGPSandWGBSshowthat,
in hepatoma cell line 97L cells, the alignment rate of GPS is 80.9%,
almost 15%–20% higher than that of WGBS analyzed by either
BSMAP or Bismark (Krueger and Andrews 2011) with about 0.4 bil-
lion reads (Fig. 1C; Supplemental Table S1). DNA methylation is
highly correlated on the commonly detected CpG sites (r=0.89,
P-value <2.2 ×10−16, Pearson correlation coefficient) with both
methods (Supplemental Fig. S1C,D). Further analyses demonstrate
thatGPShashigher efficiencywhendetectingDNAmethylation in
the repetitive elements, CpG islands, and GC-rich region such as
promoter regions (Fig. 1D–F; Supplemental Fig. S2). Moreover,
the methylation sites detected by GPS have no distribution bias
in promoter and functional genome elements (Fig. 1G), and GPS
ismore accurate thanWGBSas verified bybisulfitepyrosequencing
(Supplemental Fig. S1E). GPS is more cost-effective compared with
WGBS (Supplemental Table S2). Screenshots of UCSC Genome
Browser showed that GPS detected more CpG sites than public
WGBS data sets in CpG islands and repetitive regions (Supplemen-
tal Fig. S1F,G). Taken together, GPS is a powerful tool with signifi-
cant advantages over WGBS in detecting genome-wide DNA
methylation.
To investigate the effects of DNAmethylation patterns on tu-
morigenesis, we applied GPS to detect global DNA methylation in
normal liver andcompared itwith twohepatomacell lines, 97Land
LM3 (Supplemental Methods). In human normal liver cells (Liver,
for short), GPS detected 54,853,393 of the total 56,434,896 (97%)
CpG sites. As for all the cytosines in Liver, 1,123,233,333 of the to-
tal 1,170,378,405 cytosines (96%) are covered by at least one read
(Supplemental Table S3). This indicates that GPS is an effective
method for detecting both CpG and non-CpGmethylation. In ad-
dition, GPS detected 99.66% (7348/7373) of the cytosines in the
mitochondrial genome. The coverage rate of autosome is higher
than 96%,whereas that of theX andYChromosome is∼90% (Sup-
plemental Fig. S3A). GPS detected more CpG sites than WGBS in
each chromosome with the same number of bisulfite-converted
reads in 97L (Supplemental Fig. S3B). To validate the GPS-detected
methylation, we selected regions with distinct methylation levels
that were then confirmed by bisulfite TA clone sequencing (Fig.
1H). Moreover, we validated 13 additional regions using bisulfite
pyrosequencing, the results of which continue to demonstrate
the efficiencyofGPS indetecting globalDNAmethylation (Supple-
mental Fig. S3C,D).
We next compared GPS with WGBS in detecting genetic var-
iants and found that more genetic variants were detected by GPS
than by WGBS with the same raw reads. We found 91% of the
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2,296,462 variations detected in Liver cells overlap with those in
the dbSNP database. By comparing Liver and two hepatoma cell
lines with metastasis potential to the lung, we also found that
three potential mutants in hepatoma cell lines are located in the
lung-related gene CAV2, which were validated by bisulfite pyrose-
quencing (Supplemental Fig. S4). This suggests that GPS can simul-
taneously obtain genome as well as epigenome information in one
go, and can, therefore, assist in investigating the crosstalk between
genome and epigenome such as allele specific methylation (ASM).
For example, we identified 1820 ASMs by GPS as compared to 135
ASMs byWGBSwith the same amount of data. TwoASMs detected
byGPSwere verified by TA clone bisulfite sequencing in hepatoma
97L cells, which are locatedwithin theCCDC97 andTOP1MT gene
enrichedwith transcription factor andDNase I hypersensitive sites
(Supplemental Fig. S5). As such,GPS is able to accurately detect not






Figure 1. Guide Positioning Sequencing (GPS) detects genome-wide DNA methylation accurately with high coverage rate. (A) Schematic of GPS work-
flow for DNAmethylation detection. The gray line represents original DNA sequence, and the orange line represents DNA treated by T4 DNA polymerase,
which replaces cytosine with 5′-methylcytosine at 3′ end of DNA fragment. The solid circle (●) represents methylated cytosine, and the open circle (○)
represents unmethylated cytosine, whereas the triangle (Δ) represents thymine. Blue and green short lines represent the NGS linker. Read1 represents
the bisulfite-converted 5′ end of fragments, whereas Read2 represents the 3′ end of fragments, which is the same as the genome sequence due to 5′-meth-
ylcytosine replacement. (B) The accurate alignment rate of Bowtie 2 and GPS is obviously higher than that in BSMAP based on simulated data: (∗∗∗) P<
0.001, one-tailed paired t-test. (C) Alignment efficiency of GPS compared with WGBS. DNA methylation of 97L cells was detected in parallel by GPS
and WGBS, and mapped percentage of paired reads in GPS is 80.9%, 15%–20% higher than two popular WGBS alignment tools, BSMAP and Bismark.
(D) Performance of GPS in detecting DNAmethylation of repetitive elements. GPS had advantage over WGBS in detecting CpG sites of repetitive elements,
especially in Low complexity, SINE, and LTR. The y-axis indicates the ratio (%) of WGBS/GPS-covered CpG sites. (E) Performance of GPS in CpG islands and
CpG shores comparedwithWGBS.WGBS only detected∼43%CpGs of those by GPS in CpG islands under similar sequencing depth formethylation detec-
tion. (F) Performance of GPS in different GC content. (G) Distributions of original genomic, GPS-detected, and WGBS-detected CpG sites. Genomic dis-
tribution shows total CpG sites in the genome. GPS detected that distribution of CpG sites is more similar to the original genomic CpG distribution
compared with WGBS. (H) GPS-detected DNA methylation verified by Sanger sequencing from bisulfite-treated DNA. The red bar represents a single cy-
tosine site, and the height of the red bar represents the methylation level. Each column of circles represents a single cytosine corresponding to the red bar.
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Methylation of gene body difference to promoter
correspondingly predicts gene expression related
to tumor metabolism and immune surveillance network
To investigate the effects of DNA methylation patterns on tumor-
igenesis, we grouped genes by their expression (FPKM) and found
that in general, gene expression is associated with DNA methyla-
tion in the promoter (±1 kbp around TSS from RefSeq) as well as
in the gene body (Fig. 2A). Genes with higher expression usually
acquire lower promoter methylation and higher gene body meth-
ylation. However, we found that when gene expression FPKM is
over 20, DNAmethylation in the gene body is no longer positively
related to gene expression. Genes with expression over 20 FPKM
are more hypomethylated in the gene body, shorter in length,
more conserved, and enriched inmetabolic processes (Supplemen-
tal Fig. S6). Since DNA methylation level in either promoter or
gene body independently is not significantly correlated to gene ex-
pression, we determined to investigate whether combining the
DNAmethylation of gene body and promoter can serve as a better
predictor for gene expression.
We plotted a scatter diagram to show the numerical DNA
methylation difference between gene body and promoter regions
(MeGDP, i.e., methylation of gene body difference to promoter)
in correlation with gene expression in 97L cells (Fig. 2B; Supple-
mental Table S4). The fitted curve shows the following trends:
Within expression range FPKM 0–1, MeGDP increases at a steep
rate; within expression range FPKM 1–5, the curve levels off with
a much slower rate of increase; and within expression range
FPKM 5–20, there is little if any rate of
change. We found similar results when
we grouped genes according to FPKM by
bar plots (Supplemental Fig. S7A).
Collectively, these data indicate that the
MeGDP may be an on/off switch (FPKM
0–1) for gene expression. Furthermore,
we found that MeGDP and gene expres-
sion are correlated with rho as high as
0.67 (P-value <2.2 ×10−16, Spearman’s
rank correlation), suggesting that MeGDP
is a considerably useful predictor for gene
expression. Meanwhile, the coefficient
calculated by WGBS data set is 0.33 (Sup-
plemental Fig. S7B), which may be due to
the limitations ofWGBS, such as inaccura-
cy and lower coverage in GC-rich regions
and repetitive elements compared to GPS.
In addition, H3K4me3 and H3K36
me3 enrichment also show high correla-
tion with various levels of gene expres-
sion, even when FPKM is above 20
(Supplemental Fig. S8). When gene ex-
pression FPKM is greater than 5, H3K4
me3 or H3K36me3 enrichment is still
positively correlated with gene expres-
sion (Fig. 2C). We made similar ob-
servations in Liver and LM3 cells
(Supplemental Fig. S7C,D). These results
demonstrate the effect of histonemethyl-
ations on gene regulation.
To further investigate the rela-
tionship between gene expression and
MeGDP in tumorigenesis, we selected
down-regulatedgenes in97Lcells that ex-
hibit a decrease in MeGDP as compared
to normal liver cells to perform Gene
Ontology (GO) analysis (Fig. 2D). We
found that this set of genes is enriched
in the immune system process andmeta-
bolic process, which have been shown to
be involved in tumorigenesis. These re-
sults may help us to understand the
mechanism of cancer cell escape from
the immune surveillance system in an
alternative way, by which internal im-
mune-related molecules might be epi-






Figure 2. DNA methylation difference between gene body and promoter coordinates in regulating
gene expression related to tumor-immune surveillance network. (A) Distribution of methylation level
on promoter and gene body according to gene expression of FPKM (Fragments Per Kilobase of exon
per Million fragments mapped) in Liver and hepatoma cell line 97L and LM3. Grouped genes are based
on FPKM as FPKM=0, 0–1, 1–5, 5–20, and more than 20. Highly expressed genes exhibit gene body
hypermethylation and promoter hypomethylation and vice versa, except genes with FPKM more than
20 (red line). (B) Correlation between DNA methylation and gene expression FPKM in 97L with a
Spearman’s rank correlation coefficient of 0.67. The y-axis represents the numeral methylation difference
between gene body and promoter, and the x-axis represents the gene FPKM. (C ) Correlation between
gene expression and H3K4me3 in promoter (left) or H3K36me3 in gene body (right) in 97L. Both
H3K4me3 and H3K36me3 are positively correlated with gene expression when FPKM is more than
5. (D) Immune surveillance and tumor metabolism-related genes associated with aberrant DNA methyl-
ation. Decreased expressed genes withMeGDP reduction in 97L compared with Liver are enriched in GO
terms correlated with tumorigenesis, like immune system process, response to stimulus as well as meta-
bolic process and biological adhesion. (E) Gene expression of 102 interferon gamma pathway genes re-
lated to immune surveillance is down-regulated in hepatoma cells compared with Liver, whereMeGDP is
decreased accordingly. Wilcoxon matched pairs test: (∗∗) P-value <0.01; (∗∗∗) P-value <0.001.
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methylation during tumor development. It is known that DNA
methyltransferase inhibitors can up-regulate immune signaling
in cancer through the viral defense pathway and reverse tumor-im-
mune evasion, whichmay also modulate the epigenetic states of T
cell phenotypes, as DNA methylation can act as a regulator for
programming of T cell exhaustion and rejuvenation (Chiappinelli
et al. 2015;Ghoneimetal. 2017;Topperet al. 2017).Recently, it has
been reported that mutation or copy number loss of immune sur-
veillance-related interferon gamma (IFNG) pathway genes is inter-
preted as a failure to respond to anti-CALA4 inmelanoma patients
(Gao et al. 2016). Similarly, we found that IFNG pathway genes are
down-regulated in hepatoma cell lines, and MeGDP is reduced
accordingly (P-value <0.001, one-tail Wilcoxon signed-rank test)
(Fig. 2E), where expression and MeGDP are highly correlated (ρ=
0.62, P-value=5.8 ×10−11, Spearman’s rank correlation). Accord-
ingly, we found that immune-related genes EDNRB, ACP5, and
BST2 were all up-regulated by about two- to 75-fold after 5-AZA
demethylation treatment (Supplemental Fig. S9). We also selected
up-regulated genes in 97L cells that exhibit an increase in MeGDP
as compared to normal liver cells to perform GO analysis (Supple-
mental Fig. S10). Therefore, we conclude that the reactivation of
immunological surveillance genes in tumor cells by selective
DNA methylation inhibition may be an alternative strategy in
anti-tumor immunotherapy.
Methylation Boundary Shift in the promoter region modulates
tumor-related ribosomal gene expression
AlthoughthepatternofDNAmethylation in thepromoter region is
known to be in a “V” shape, the groove of the hematoma cell lines
has shown a much wider opening than that of normal liver cells,
suggesting that tumor cellsmay havemuch broader hypomethyla-
tion in the promoter region. We termed the DNA methylation
boundary extension around transcription start site (TSS) as the
Methylation Boundary Shift (MBS). To further investigate the ex-
tension of MBS in promoter, we selected genes with broadened
MBS in 97L as compared to Liver cells and arranged the genes ac-
cording to the length and direction of theDNAmethylation exten-
sion from TSS (Fig. 3A). We categorized two groups of genes based
on the direction of the MBS extension, direction to downstream,
and direction to upstream of TSS. A similar MBS pattern can also
be found in LM3 and primary liver cancer cells (Supplemental
Fig. S11A,B).Weobserved thatH3K4me3andH3K36me3aremutu-
ally exclusive within the MBS region, consistent with their role as
the marker for active genes. Meanwhile, the boundary of the MBS
extension also highly coincides with H3K4me3 and H3K36me3
patterns (Fig. 3B).
To investigate the role ofMBS in gene regulation, we analyzed
the length of the MBS extension with corresponding gene expres-
sion level. By comparing 97Lwith Liver onhighly expressed genes,
we found that the length of the MBS extension downstream from
TSS is positively correlated with the increase of gene expression
(Fig. 3C), whereas the MBS extension to the upstream or promoter
methylation alteration shows no obvious correlation with gene
expression (Supplemental Fig. S11C). We observed similar results
when comparing LM3 or primary liver cancer cells to Liver
(Supplemental Fig. S11D,E). For example, oncogene MYC expres-
sion increased with the MBS extension downstream from TSS
(Fig. 3D) and the MBS extension had been further verified by
Sanger bisulfite sequencing (Fig. 3E). Moreover, MBS extension
downstream from TSS coincides with the H3K4me3 peak length
correspondingly (Fig. 3F), and the H3K4me3 peak length was re-
ported to be involved in gene expression related to cell identity
and tumorigenesis (Benayoun et al. 2014; Chen et al. 2015; Dahl
et al. 2016). Here, we demonstrated that both MBS and H3K4me3
peak length is in fact positively correlated with gene expression
(Supplemental Fig. S11F). Taken together, these results indicate
that MBS in the promoter region may play an important role in
modulating gene expression.
Next, we performed KEGG analysis for up-regulated genes in
97L cells with downstream MBS extension and found that these
selected genes are enriched in pathways including ribosome and
cell cycle (Fig. 3G; Supplemental Fig. S12A). We found that 48 of
60 up-regulated ribosomal genes with MBS were identified by
GPS, but only seven by WGBS (Supplemental Fig. 12B,C). There-
fore, MBS may contribute to the increased expression of ribosome
biogenesis genes and consequently promote cell proliferation and
transformation.
To further validate the correlation of gene expression and
MeGDP or MBS, we performed GPS in two breast cell lines,
MCF-10A and MCF-10A-1H (Zheng et al. 2018). We found the
correlationbetween gene expression andMeGDPorMBSwere con-
sistent with the previous results (Supplemental Fig. S13A–C),
whichwere also verified byother publicWGBSdata (Supplemental
Fig. S13D–G).
Methylation Boundary Shift in enhancers promotes gene
expression related to tumorigenesis
Like the promoter, the enhancer is another kind of regulatory ele-
ment that correlates with DNA methylation (Aran and Hellman
2013;Honet al. 2013). Theremight be severalmillions of enhancer
elements embedded in the human genome, in whichH3K27ac is a
notable histone modification that marks the active enhancer
(Creyghtonet al. 2010; Shenet al. 2012).Given thatMBSextension
in the promoter region is clearly correlated with gene expression,
wedecided to explorewhetherMBSmayalso occur in the enhancer
region during tumorigenesis. We sorted the predicted enhancers
according to the length of H3K27ac peaks and compared them
with the corresponding DNA methylation pattern. The width of
H3K27ac peaks also coordinated with MBS in Liver as well as in
97L and LM3 cells (Fig. 4A; Supplemental Fig. S14A), indicating
that MBS may also have regulatory effects on enhancers as well as
the shaping of promoter activity to regulate gene expression.
Compared with the normal liver cells, we discovered that 97L
cells gained a set of enhancers and lost another set, and the chang-
es of enhancers are coupled with DNAmethylation alteration (Fig.
4B). GO analysis showed that genes that gain enhancers in 97L are
enriched in developmental maturation and forebrain develop-
ment, whereas genes that lose enhancers are enriched in the regu-
lation of cell motion as well as T cell differentiation and activation,
both of which are closely associated with tumorigenesis. Apart
from enhancer gain or loss above, we also grouped enhancers by
enhancer length extension, no extension, and reverse extension
in 97L compared to Liver (Fig. 4B). Corresponding methylation
levels for each enhancer show the consistency between enhancer
length and MBS. GO analysis shows that genes with enhancer ex-
tension are enriched in lung development, and genes with en-
hancer reverse extension are enriched in the regulation of T cell
activation, which are important to cell identity and tumorigenesis,
respectively. In addition, five enhancer patterns show significant
differences in the up- and down-regulated genes comparing 97L
to Liver (P-value=7.6 ×10−13, χ2 test) (Fig. 4B), where gained/
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lost/reversely extended enhancers. Moreover, analysis of enhanc-
ers in comparing Liver versus LM3 also shows similar results
(Supplemental Fig. S14B). Seeing that LM3 is derived from 97L
and can easily metastasize to lung, gain or loss of enhancers is sig-
nificantly less when comparing 97L versus LM3 (Supplemental
Fig. S14C), indicating that 97L and LM3 are more similar except
for their metastasis properties. Furthermore, genes that gained or
lost enhancers between 97L and LM3 are enriched in lymphocyte
proliferation and response to drugs, respectively. Meanwhile,






Figure 3. Methylation Boundary Shift (MBS) in the promoter region modulates gene expression. (A) MBS in 97L cells displaying MBS extension to the
upstream or downstream from TSS compared with Liver cells. Genes are arranged from top to bottom according to the length and direction of MBS.
(B) H3K4me3 and H3K36me3 in 97L display a mutually exclusive enrichment within the MBS region. H3K4me3 enrichment and length are in agreement
with MBS, where H3K36me3 is mutually exclusive. (C) MBS extension is positively related to gene expression in the box plot. The x-axis is the delta MBS
(difference between 97L and Liver), and the y-axis is the 97L/Liver expression ratio. Gene expression is up-regulated with theMBS increase. Schematic MBS
is displayed in the upper panel. (D)MBS is related toMYC up-regulation in hepatoma cells. Smoothedmethylation (in red) shows theMBS to downstream in
hepatoma cells, whereasMYC expression (in blue) is increased comparedwith liver cells. (E)MBS in the promoter ofMYC is observed and verified by bisulfite
sequencing PCR in three sequential loci (black block). Each red line represents a CpG site, and its height represents methylation level (upper). Each column
represents a CpG site, and each line represents a picked TA clone by Sanger sequencing. Red blocks represent methylated CpGs, and blue blocks represent
unmethylated CpGs (lower). (F ) Length of the H3K4me3 peak is positively correlated with MBS downstream from TSS. The y-axis represents the length of
the H3K4me3 peak, and the x-axis is the MBS extension downstream from TSS. (G) Ribosomal genes are significantly enriched in genes whose up-regu-
lation is accompanied byMBS. Compared with liver cells, KEGG analysis displays that up-regulated genes withMBS extension downstream from TSS in 97L
are enriched in terms such as ribosome and cell cycle, which are important for tumorigenesis.
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for positive regulation of cell differentiation as well as glucosemet-
abolic process, which contributes to our understanding of the
metastasis properties of LM3. Together, these results suggest that
aberrant DNA methylation pattern in the enhancer region may
modulate enhancer features and regulate gene expression, which
further shapes tumor cell behavior during tumorigenesis and
metastasis.
Aberrant DNA methylation patterns induce gain or loss of cell
identity through enhancer switching, resulting in tumorigenesis
and metastasis
Human cells and tissues maintain cell identity by expressing cell-
type–specific genes, which are controlled by tissue-specific en-
hancers or other related epigenetic components. In turn, cells
can lose their identity once the expression of their own cell-type–
specific gene expression is reduced, or when other cell-type–specif-
ic genes are expressedduring tumordevelopment (Heintzmanet al.
2009; Roadmap Epigenomics Consortium et al. 2015). Knowing
this, we focused on the analysis of the tissue-specific genes and
enhancers. We found that the number of highly expressed liver-
specific genes in 97L and LM3 is reduced by 74% and 80%, respec-
tively, as compared to Liver. Meanwhile, the number of lung-spe-
cific genes (ICAM1 for instance) as well as testis (COIL), stomach
(ZDHHC18), heart (MAPKAPK2), and colon (MAX) tissue-specific
genes (Pan et al. 2013) increased in 97L and LM3 cells, indicating
that hepatoma cells have lost their identity and adopted character-
istics of other cell types during the tumordevelopmentprocess.We
BA
Figure 4. MBS is in accordance with enhancer alteration. (A) Methylation boundary shift in enhancer region. Enhancer is defined as the H3K27ac peak
except those located in promoter region (TSS ±1 kb). Enhancers are arranged according to the H3K27ac peak length in Liver, and methylation level of the
enhancer is shown in the same order as H3K27ac peaks. (B) General enhancer alteration including gain/loss and length variation coordinately with aberrant
DNAmethylation in 97L cells. A–E are classified as follows: A (97L-specific enhancer); B (Liver-specific enhancer); C (enhancer in 97L cells with width at least
500 bp more than that in Liver); D (enhancer in 97L or Liver cells extends <500 bp); and E (enhancer in Liver with width at least 500 bp more than that in
97L cells). A–E represent enhancer gain, loss, extension, no extension, and reverse extension, respectively, in 97L compared with Liver cells with corre-
sponding aberrant DNA methylation in the right column. Percentage of up-regulated (red bar) and down-regulated genes (blue bar) is significantly cor-
related with enhancer altering pattern (P-value = 7.565 ×10−13, Pearson’s χ2 test). Gene Ontology analyses show that genes coordinated with enhancer
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found that there are more lung-specific genes in LM3 than in 97L
cells, consistentwith the fact that LM3 ismoreprone to lungmetas-
tasis (Fig. 5A; Supplemental Fig. S14D). Thus, the lung-specific
genes expressed in LM3 might aid the LM3 cells in adopting fea-
tures of the lung and surviving in the lung environment.
Since it is well known that enhancers are tissue-specific, we
conducted analysis on the tissue-specific enhancers and aberrant
DNA methylation in hepatoma cells. Accordingly, we found that
the number of liver-specific enhancers was reduced in 97L and
LM3 cells compared to Liver, whereas the number of lung-specific
enhancers increased in 97L and LM3 cells. As expected, there are
more lung-specific enhancers in LM3 than in 97L cells, consistent
with the lung-specific genes (Fig. 5B). Moreover, the gain of
lung-specific enhancers is associated with DNA methylation re-
duction, and the loss of liver-specific enhancers is associated
with DNA methylation increase in 97L and LM3 cells (Fig. 5C),
suggesting that aberrant DNA methyla-
tion is correlated with cell identity
changes by altering the tissue-specific
enhancer. Meanwhile, the loss or gain
of cell identities accompanied by aber-
rant DNA methylation is an alternative
process during tumorigenesis, and hepa-
toma metastasis is associated with the
expression of lung-specific genes, which
facilitates the adaptation of liver cancer-
ous cells in the lung environment. For
example,ONECUT2, a liver-specific gene,
is silenced in 97L and LM3 cells and is
coupled with a loss of H3K27ac peak
and gain of DNA methylation in a near-
by liver-specific enhancer region (Fig.
5D). On the other hand, we observed
that increased expression of CKS2 in
97L and LM3, a lung-specific gene, is
coupled with an increased level of
H3K27ac and decreased DNA methyla-
tion in a lung-specific enhancer (Fig.
5E). Hence, these results imply that aber-
rant DNAmethylation pattern in the en-
hancer region may modulate enhancer
switching, which in turn affect its target
gene expression and further shape tumor
cell behavior during tumorigenesis
and metastasis. This scenario is an ele-
gant illustration for interpreting tumor
metastasis.
Our findings here demonstrate that
lung-specific genes expressed in LM3
cellsmayhave aided them to better adapt
and survive in the lung environment, in-
dicating that the loss of cell type identity
and gain of other cell identity is a critical
turning point during tumor develop-
ment, which also provide an alternative
way to understand organ-specific tumor
metastasis.
Discussion
The diploid human epigenome contains
more than 109 cytosines, of which ap-
proximately one-twentieth are CpGs. Methylated cytosines, in
particular, are stable epigenetic marks that can be passed onto
the next generation. Furthermore, DNA methylation patterns
have been regarded as a transcript of environmental exposures in
one’s lifetime andhave been used as biomarkers for disease diagno-
sis and risk detection. Dynamic DNA methylation can occur at ei-
ther distinct regions of the genome or the same region but with
varying levels. It is known that transcription factors tend to bind
at Low Methylated Regions (LMRs), which display tissue-specific
or developmental stage–specific patterns (Feldmann et al. 2013).
The interplay between LMRs and TF is usually associated with
changes in enhancer function, which further influences gene ex-
pression and cell state.
Variation in DNA methylation can take place at single cyto-
sine sites, known as a methylation variable position (MVP), or sin-




Figure 5. Aberrant DNA methylation pattern is correlated with enhancer alteration and cell identity.
(A) 97L and LM3 lose the identity of liver by losing the liver-specific gene expression while they gain
lung cell identity by expressing the lung-specific gene. The y-axis shows the number of highly expressed
genes (FPKM ≥5). There are more lung-specific genes in LM3 cells compared with 97L cells. (B) Tissue-
specific enhancers altered accordingly in 97L and LM3 with preferential metastasis to lung. For liver-spe-
cific enhancers, the number of overlapped H3K27ac peaks sequentially decrease in Liver, 97L, and LM3,
which is related to loss of liver cell identity, whereas lung-specific enhancer is increased, especially in LM3
cells, which may promote expression of lung-specific genes, further helping LM3 cells metastasize to
lung. (C) Loss or gain of tissue-specific enhancer is correlated with DNA methylation. Column 1 (blue
bar) shows liver tissue-specific enhancers lost in hepatoma cells are accompanied by increased DNA
methylation, and Column 2 (green bar) shows lung tissue-specific enhancers that are gained in hepato-
ma cells might be induced by largely decreased DNA methylation. The y-axis represents normalized and
comparable methylation difference. Liver versus 97L is displayed in the upper panel, whereas the Liver
versus LM3 is in the lower panel. (D) Tissue-specific enhancer gain or loss with aberrant DNAmethylation
is correlated with tissue-specific gene expression. Liver-specific gene ONECUT2 is down-regulated in 97L
and LM3 with the loss of liver-specific enhancer where DNA methylation is increased. (E) Lung-related
gene CKS2 is up-regulated in 97L and LM3 cells with gain of lung-specific enhancer where DNA meth-
ylation is decreased.
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SNP. Accurately capturing SMP or low-level DNAmethylation pat-
terns is critical for studying their impact on human diseases.
Current strategies for detectingDNAmethylation genome-wide in-
clude (1) using a restriction enzyme to differentiate and recognize
methylated versus unmethylated cytosine bases; (2) immuno-
precipitation of methylated DNA; and (3) bisulfite treatment that
converts unmethylated cytosines to uracils while leaving methyl-
ated cytosines unchanged. Among them, WGBS is currently the
most popular method; however, as we mentioned before, WGBS
bioinformatics analysis is usually based on either wild-card or
three-letter aligners and tends towaste a large proportion of the se-
quencing reads (Kunde-Ramamoorthyet al. 2014; Plongthongkum
et al. 2014; Marx 2016). To reconcile this problem, we developed
the GPS method, in which the first part of the pair-ended read is
the original DNA sequence and the second part of the read pair is
bisulfite-converted sequence. Since the first read can be accurately
mapped to the reference genome, it can serve as guide for the sec-
ond read. GPS has high DNA methylation coverage rate, at nearly
96%of the human liver genome and can also detect strand-specific
whole-genomemethylome. Compared withWGBS, the advantag-
es of GPS include higher cytosine coverage, especially in CpG
islands and repetitive elements, and higher accuracy in DNA
methylation detection as verified by bisulfite pyrosequencing.
Moreover, it candetectbothgenetic informationandepigenetic in-
formation in a single experiment, which is important for samples
with limited DNA, such as single cells. GPS is a powerful tool for
studying global DNAmethylation patterns and their effects on hu-
man diseases.
Extensive literature has shown that the accumulation of ge-
netic and epigenetic abnormalities is related to cancer. Through re-
verse genetic methods, the role of genetic alterations in cancer
development has been well illustrated. However, the role of epige-
netic alterations in cancer has not been shown equallywell. For ex-
ample, little is known about the interactions between the
promoter and gene body methylation. Our results indicate that
gene expression is correlated with the methylation level of gene
body difference to promoter (MeGDP), suggesting that methyla-
tion in promoter and gene body may work in a collaborative man-
ner to activate gene expression. Further analysis shows that genes
associated with MeGDP are involved in the immune system pro-
cess, in which the equilibrium of cancer cells versus host immune
surveillancemay be disrupted, resulting in edited immunogenicity
by immunoepigenetics toweaken immune responses and promote
clinically apparent cancers, which may help us to understand the
limited response of current immune therapy by blocking PD-1/PD-
L1, and DNMT inhibitors may reverse the immune signals of can-
cer cell for the basis of epigenetic therapy in clinic trials (Jones et al.
2016).
Furthermore, Methylation Boundary Shift in the promoter
and enhancer regions as a specific pattern of DNA methylation
may alter gene expression, especially in highly expressed genes.
We found that MBS expansion in cancer cells is closely associated
with ribosomal gene expression, which is related to nucleolus
function and involved in tumorigenesis. MBS is also supported
by the finding that hypomethylated regions expand and contract
with lineage specificity in the adult hematopoietic compartment
(Hodges et al. 2011). Meanwhile, the liver cancer–specific shorten-
ing ofMBS are accompaniedwith expression reduction of immune
and immune escape–related genes, which can also play an essen-
tial role in immune surveillance.
Tumor metastasis is the process by which malignant tumor
cells penetrate the wall of lymphatic or blood vessels and circulate
to other sites through the bloodstream and eventually form anoth-
er clinically detectable tumor. In this scenario, it is difficult for
cancer cells to survive outside their region of origin, and therefore
the metastasizing tumor cells must either find a location with
similar characteristics or remodel and adapt themselves to the
new environment for assimilated symbiosis. In support of this
“Assimilated Symbiosis” theory, we showed that LM3 cells, which
can easily metastasize to lung, have altered DNA methylation pat-
terns with reduced liver-specific genes and increased lung-specific
genes. We also analyzed DNA methylation in the liver- and lung-
specific enhancer regions in 97L and LM3 cells, which altered ac-
cordingly as well, suggesting DNA methylation mediates cancer
metastasis by shaping tumor cell behavior to environment. Our re-
sults suggest that liver cells may lose their identity and gain the
lung cell identity to adapt to the lung environment through aber-
rant DNA methylation, which provide a new insight for under-
standing the mechanism of tumor metastasis.
In summary, GPS can unbiasedly and precisely detect the
DNA methylome, especially in GC-rich and repetitive regions as
compared to WGBS. MeGDP and MBS may act as effective param-
eters in gene regulation related to immunity and tumor metabo-
lism. Meanwhile, aberrant DNA methylation in tissue-specific
enhancers may contribute to altering cell identity and help us to




Genomic DNA from tissues and cell lines was extracted using
QIAamp DNA Mini Kit (Qiagen, 51306). Genomic DNA was frag-
mented into 300–500 bp by sonication using bioruptor
(Diagenode, Bioruptor plus). Thirty units of T4 DNA polymerase
(New England BioLabs, M0203L) was used to perform 3′→5′ diges-
tion of the DNA fragments for 100min at 12°C followed by adding
10 µL dNTPmixwhich contained dATP, dTTP, dGTP, and 5′-meth-
yl-dCTP nucleotide (final concentration 0.5 mM) and incubating
for 30 min at 37°C. Then, A-tailing was performed by klenow frag-
ment (3′→5′ exo-) from NEB (M0212L), and methylated adapter
was ligated to DNA fragments using T4 DNA ligase from NEB
(M0203L) according to the manufacturer’s instruction. The frag-
ments were size-selected and processed to bisulfite conversion,
CT-transformed DNA was amplified with the KAPA HiFi Uracil +
DNA Polymerase (KAPA Biosystems, KM2801) using Illumina
TruSeq primers, fragments between 400 and 500 bp were selected
for high-throughput sequencing on Hi Seq 2500 (Illumina). Spike-
in lambda DNA (Promega, D150A) was added at a mass ratio of
1/200 for bisulfite conversion testing.
Adjustment for GPS Read2 and Read1
We first performed quality control and adapter trimming using
NGS QC Toolkit v2.3.3. The GPS library was sequenced using
Illumina HiSeq 2500 with pair end (2×100 bp). According to the
GPS library construction, the unmethylated cytosine (C) in
Read1 was converted into thymine (T) by bisulfite treatment cou-
pled with PCR amplification, while the C in Read2 was not con-
verted into T, so that the sequence in Read2 was the same as the
sequence of the reference genome. However, due to possible insuf-
ficiency in T4DNApolymerase treatment, theremay exist the con-
versions of C→T in 3′-end of Read2. These conversions in Read2
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To minimize such influence, we searched the sequencing
boundary between treated and not treated by T4 DNA polymerase
(Supplemental Fig. S15). If the T4 DNA polymerase sufficiently
treated the 3′-end of the fragment, the cytosines (Cs) in the
3′-end of the fragment could be all methylated. Otherwise, the
unmethylated Cs could exist in the fragment, especially proximate
to the 5′-end, and these unmethylated Cs could be converted into
Ts after bisulfite treatment. The complement nucleobase of the
C-converted T in the opposite strand was G-converted A in
Read2. According to the Illumina pair-end sequencing principle,
the Read2 is located in the 3′-end opposite strand of the fragment.
So the methylated and unmethylated C were presented as G and A
in Read2, respectively, due to the complement of C=G and T=A.
Due to the methylation level of C in CH (H is A, T, C), context is
generally very low, if the methylated CH was found, it suggests
the T4 polymerase treatment was sufficient, otherwise it was insuf-
ficient. The corresponding sequences of the methylated CH in
Read2 were 3′-G[A/T/G]-5′. So, we scanned Read2 from 5′- to
3′-end to find the last 3′-G[A/T/G]-5′, which was treated as the
boundary between treated and not treated by T4 polymerase.
The Read2 sequence between the boundary and the 3′-endwas dis-
carded, and the remaining was used for aligning onto the genome.
If the length of the remaining read was <35 bp, the read would also
be discarded. We also noticed that, in the case of samples with
high methylated CH, such as neuronal tissue, the CHs were sub-
stantially methylated and would remain cytosine after bisulfite
treatment whether T4 polymerase-treated or not. However, analy-
sis showed high efficiency of T4 polymerase in GPS experiment, so
that high methylated CHs would have a minor effect on the map-
ping efficiency.
Conversely, there also exists overtreatment of T4 polymerase,
which also possibly induced over methylation in the 3′-end of
Read1. To overcome such potential bias, we scanned Read1 from
the 3′- to the 5′-end to find the first conversion of C/T, which
was defined as a boundary between nontreatment and treatment
of T4 polymerase. The sequence between the boundary and
5′-end of Read1 was used for methylation calling (Supplemental
Fig. S15).
GPS alignment
Adjusted Read2s were aligned onto the reference genome (hg19)
using Bowtie 2 (v2.2.3) (Langmead and Salzberg 2012)with default
parameters except “-k 20”, which allows to output up to 20 candi-
date mapping positions. Statistically, there are 56,434,896 CpG
sites in the human reference assembly GRCh37 (hg19) and
58,690,664 CpG sites in GRCh38 (hg38), with 96% common
CpG sites in both references. Thus, realigning the reads to
GRCh38 (hg38) would not significantly affect the conclusions.
After the alignment of Read2, the fragments were anchored
into the genome. According to the Illumina sequencing specifica-
tion, the Read1 is located in the opposite strand downstream from
the corresponding Read2. The fragment size in the GPS library was
approximately 400–500 bp. We used the Smith-Waterman, an al-
gorithm of local sequence alignment, to map the Read1 to the ref-
erence target sequence that was locatedwithin 1 kb of the opposite
strand downstream from the Read2. The algorithm first built a
score matrix as follows:
F(i, 0) = 0, 1 ≤ i ≤ m
F(0, j) = 0, 1 ≤ j ≤ n
F(i, j) =max
0 (i = 0 or j = 0)
F(i− 1, j− 1)+ s(S[i], T[j])
F(i− 1, j)+ s(−, j)







, 1 ≤ i ≤ m, 1 ≤ j ≤ n
s(S[i], T[j]) =
+5 if S[i] = T[j] or C is converted to T
0 if S[i]! = T[j]







where S= sequence from Read1; T= sequence from reference ge-
nome; S[i],T[ j] = ith nucleobase in S, and jth in T; m= length of
S; and n= length of T.
To obtain the optimum local alignment, our script started
with the highest value in the matrix F(i, j). Then, go backward to
one of positions (i−1, j), (i, j−1), and (i−1, j−1), depending on the
direction ofmovement used to construct thematrix. Thismethod-
ology is maintained until a matrix cell with zero value is reached.
Finally, the alignment is reconstructed as follows: Starting with
the highest value, reach (i, j) using the previously calculated
path.Adiagonal jumpimplies there is analignment (eitheramatch
or a mismatch). A bottom-up jump implies there is an insertion. A
right-left jump implies there is a deletion. The Smith-Waterman al-
lows exactly aligning Read1 onto the reference genomewith toler-
ance of C/T mismatch. For each cytosine, we counted the number
of “T” (NT) and the number of “C” (NC). Themethylation percent-
age in the cytosine is defined as NC/(NC+NT) × 100%.
Data access
Raw and aligned sequencing data from this study have been sub-
mitted to the NCBI Gene Expression Omnibus (GEO; http://www.
ncbi.nlm.nih.gov/geo/) under accession number GSE92328. The
GPS method is available on GitHub (https://github.com/lijinbella/
GPS) and as a Supplemental Code.
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